Parkinson Disease
Conditions
Brief summary
Parkinson's disease concerns some defects in carbohydrates metabolism involved in the progress of the pathology. Ketogenic diet has been largely studied as treatment on drug-resistant epilepsy and other neurologic diseases, but there is little information on the impact of this kind of diet in clinical aspects of Parkinson's disease. The aim of our study is thus to evaluate the effect of a lipid and protein controlled diet on resting energy expenditure, body composition and symptoms in patients with Parkinson's disease.
Detailed description
Parkinson's disease concerns some defects in carbohydrates metabolism involved in the progress of the pathology. Ketogenic diet has been largely studied as treatment on drug-resistant epilepsy and other neurologic diseases, but there is little information on the impact of this kind of diet in clinical aspects of Parkinson's disease. The aim of our study is thus to evaluate the effect of a lipid and protein controlled diet on resting energy expenditure, body composition and symptoms in Parkinson's disease patients.
Interventions
OTHERKetogenic diet
The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
Sponsors
University of Padova
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* patients with a diagnosis of Parkinson's disease, treated with L-Dopa or other dopaminergic drugs. * Mini Mental State Examination (MMSE) \>24. * Activities of Daily Living \>3.
Exclusion criteria
* Mini nutritional assessment \<17; BMI \<18, hypoalbuminemia or lymphopenia. * acute or chronic liver diseases; * renal function impairment (Clearance creatinine \<30ml/min); * cancer; * acute inflammatory diseases; * thyroid diseases; * diabetes mellitus; * dysphagia; * dementia; * dyslipidemia; * history of recent cardiovascular or cerebrovascular events; * psychiatric diseases; * iatrogen parkinsonism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in resting energy expenditure | Baseline, week 4 and week 8 | Changes in resting energy expenditure as measured by indirect calorimetry |
Countries
Italy
Outcome results
None listed